Patrick J. Stiff

Itacitinib plus calcineurin inhibitor–based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results

Nirav Niranjan Shah, Hannah Choe, Nancy Hardy, Patrice Chevallier et autres

us, fr, es (code pays fourni par la source)

QTc Prolongation in Allogeneic Hematopoietic Stem Cell Transplantation: Assessing Cardiac Complications and Survival Outcomes

Mark F. deBettencourt, Timothy E O’Connor, Kayéromi D. Gomez, Shannon Carrigan et autres

us (code pays fourni par la source)

Evaluating gvhd outcomes after chemotherapy-only conditioning in nicotinamide-expanded umbilical cord blood (omidubicel) transplantation: A retrospective cohort study

A. Edward O’Hara, Abhilasha Kumar, Dawn Marie Stull, Kayéromi D. Gomez et autres

Abstract INTRO: Omidubicel (Omi) is an ex vivo expanded hematopoietic progenitor cell product derived from a single umbilical cord blood (UCB) unit that was FDA approved in April 2023. In the Phase III trial (P3) comparing Omi transplant (HCT) to standard UCB …

us, il (code pays fourni par la source)

QTc prolongation in allogeneic bone marrow transplantation: Assessing cardiac complications and survival outcomes in the modern era

Mark F. deBettencourt, Timothy Edward O'Connor, Kayéromi D. Gomez, Gauri Shankar et autres

Abstract Purpose/Objectives:QT interval prolongation is clinically relevant due to increased risk of sudden cardiac death from Torsades de Pointes (TdP), although rates are only 0.0025% - 0.16% for hospitalized patients. Over the past 5 years, there has been increased emphasis on QTc …

us (code pays fourni par la source)

Preventing Skeletal-Related Events in Newly Diagnosed Multiple Myeloma

Benjamin Massat, Patrick J. Stiff, Fatema Esmail, Estefania Gauto‐Mariotti et autres

Despite the increasing number of novel therapies to treat newly diagnosed multiple myeloma (NDMM), preventing skeletal-related events (SREs) remains a challenge. This review summarizes the mechanistic causes of myeloma bone disease, data supporting the use of bisphosphonates and RANKL inhibitors, and the …

us (code pays fourni par la source)

Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301/BMT-CTN 1201

Charalambos Babis Andreadis, Olivia Bobek, Eric D. Hsi, Timothy S. Fenske et autres

To improve outcomes in relapsed or refractory activated B-cell type Diffuse Large B-cell Lymphoma (ABC-DLBCL), we launched a randomized phase 3 trial evaluating 2-year progression free survival (2yPFS) with the addition of ibrutinib to autologous transplant. Patients received ibrutinib 560 mg or …

us, my, qa (code pays fourni par la source)

Maintenance therapy with azacitidine and valproic acid after allogeneic stem cell transplant in patients with high-risk myelodysplastic syndrome and acute myelogenous leukemia.

Timothy Edward O'Connor, Cody Whitcomb, Kayéromi D. Gomez, Patrick J. Stiff et autres

6578 Background: Relapse is a major cause of death after allogeneic stem cell transplant (allo-SCT) in patients with high-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Chemotherapy maintenance to prevent relapse has had limited success to date, with a phase 3 …

us (code pays fourni par la source)

Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program

Mitchell E. Horwitz, Gary John Schiller, Andrew R. Rezvani, Richard Thomas Maziarz et autres

Omidubicel-onlv is an FDA-approved, nicotinamide-modified, allogeneic hematopoietic progenitor cell therapy derived from umbilical cord blood (UCB). A phase 3 study demonstrated improved hematopoietic recovery and decreased infections with omidubicel compared with UCB allogeneic transplantation. We report results of an Expanded Access Program …

us, il (code pays fourni par la source)

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Bijal Dinesh Shah, Ryan Daniel Cassaday, Jae H. Park, Roch Houot et autres

Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 CAR T-cell therapy approved in the US to treat adults aged ≥18 years (≥26 years in the EU) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Brexu-cel showed an overall complete remission (CR)/CR with incomplete …

us, fr, de, nl (code pays fourni par la source)

Report on the First in Human Experience Using a Highly Purified CD34-Tagged CD19-Targeting CAR T Cell in Patients with Aggressive B-Cell Malignancies

Nasheed Mohammad Hossain, Oliwia Bochnacka, Gina M. Scurti, Tamson V. Moore et autres

Background Chimeric Antigen Receptor T cell (CAR-T) therapy has increased long term disease control, with 3 FDA approved CAR products now available DLBCL but only 40% of patients have a durable response and there are significant side effects, including Cytokine Release Syndrome …

us, lt (code pays fourni par la source)

CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management

Joseph Allan Norton, Patrick J. Stiff

CAR-T cell therapies have risen to prominence over the last decade, and their indications are increasing with several products approved as early as second line in Large B Cell non-Hodgkin Lymphomas. Their major toxicities are the cytokine release syndrome (CRS) and the …

us (code pays fourni par la source)

Randomized Phase III SIERRA Trial of 131 I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML

Boglarka Gyurkocza, Rajneesh P. Nath, Stuart Seropian, Hannah Kyung Choe et autres

PURPOSE Older patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate 131 I-apamistamab with conventional care. METHODS SIERRA (ClinicalTrials.gov identifier: NCT02665065 ) was a …

us, ca (code pays fourni par la source)